Long-Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice

Claire Gerber1,2, Xueyan Wang1,2,3, Valentin David1,2,3

  • 1Division of Nephrology and Hypertension, Feinberg School of Medicine Northwestern University Chicago IL USA.

JBMR Plus
|August 9, 2021
PubMed

Insights

Genetic loss of sodium-glucose cotransporter 2 (SGLT2) function in mice impaired skeletal growth and reduced bone mineral density over time. This suggests SGLT2 inhibition may contribute to long-term bone fragility, even without type 2 diabetes mellitus.

Area of Science:

  • Bone and Mineral Metabolism
  • Endocrinology
  • Nephrology

Background:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors benefit kidney and cardiovascular outcomes in type 2 diabetes mellitus (T2DM).
  • Bone fragility is a potential side effect of SGLT2 inhibitors, possibly linked to altered mineral metabolism.

Purpose of the Study:

  • To investigate the long-term effects of genetic SGLT2 loss on bone and mineral metabolism in mice.
  • To determine if SGLT2 deficiency impacts skeletal growth, microarchitecture, and mineralization independently of T2DM.

Main Methods:

  • Utilized Sweet Pee (SP) mice with a nonsense mutation in Slc5a2, leading to complete SGLT2 loss.
  • Collected urine, serum, and bone samples from 15- and 25-week-old wild-type (WT) and SP mice.
  • Assessed renal function, mineral metabolism, bone growth, microarchitecture, and mineralization.

Main Results:

  • SP mice exhibited glucosuria but maintained normal kidney function.
  • At 25 weeks, SP mice showed reduced urinary calcium excretion, increased fractional phosphate excretion, reduced body weight, and impaired femur length.
  • Cortical bone mineral density was reduced in 25-week-old SP mice, without changes in bone microarchitecture or key regulatory hormones (FGF23, PTH, 1,25(OH)2D).

Conclusions:

  • Long-term genetic loss of SGLT2 function in mice, in the absence of T2DM, is associated with impaired skeletal growth and reduced bone mineral density.
  • These findings suggest a potential mechanism by which SGLT2 inhibition could contribute to bone fragility.
  • Further research is needed to elucidate the impact of SGLT2 loss on bone fragility specifically in the context of T2DM.